CompletedPhase 2NCT06091956
A Study of Deucravacitinib to Treat LPP and FFA
Studying Lichen planopilaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Aaron Mangold, MDMayo Clinic
- Intervention
- Deucravacitinib(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (2)
- Mayo Clinic Arizona, Scottsdale, Arizona, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06091956 on ClinicalTrials.govOther trials for Lichen planopilaris
Additional recruiting or active studies for the same condition.